Your browser doesn't support javascript.
loading
Improving Oncology Clinical Programs by Use of Innovative Designs and Comparing Them via Simulations.
Marchenko, Olga; Miller, Joel; Parke, Tom; Perevozskaya, Inna; Qian, Jiang; Wang, Yanping.
Afiliação
  • Marchenko O; 1 Innovation, Quintiles, Durham, NC, USA.
  • Miller J; 2 Biometrics, Lilly Oncology, Bridgewater, NJ, USA.
  • Parke T; 3 Clinical Trial Solutions, Tessella, Abingdon, UK.
  • Perevozskaya I; 4 Biometrics, Statistical Research and Consulting Center, Pfizer Inc, Collegeville, PA, USA.
  • Qian J; 5 Statistics, Data and Statistical Sciences, AbbVie Inc, North Chicago, IL, USA.
  • Wang Y; 6 Biometrics and Advanced Analytics, Eli Lilly and Company, Indianapolis, IN, USA.
Ther Innov Regul Sci ; 47(5): 602-612, 2013 Sep.
Article em En | MEDLINE | ID: mdl-30235585
The design of an oncology clinical program is much more challenging than the design of a single study. The standard approach has been proven to be not very successful during the past decade; the failure rate of phase 3 studies in oncology is about 66%. Improving the development strategy by applying innovative statistical methods is one of the major objectives for study teams designing and supporting oncology clinical programs. However, evaluating trial design alternatives is difficult; the designs may have different advantages-better power, better type I error control, shorter duration, or more accuracy-and their relative performance may depend on assumptions about the drugs' performance. Evaluating different early phase designs in particular suffers from both these problems. This paper is built on the work of the DIA's Adaptive Design Scientific Working Group oncology subteam on an Adaptive Program. With representatives from a number of institutions, this group compared 4 hypothetical oncology development programs that each was to select between 2 treatments and decide whether to proceed to phase 3, using probability of the clinical program's success and expected net present value (eNPV). Simulated scenarios were used to motivate and illustrate the key ideas. For the development strategies, we believed that the eNPV showed a distinct and robust improvement for each successive strategy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article